Monogram Technologies said its technologies combine 3D printing, advanced machine vision, AI, and next-generation robotics. | Source: Monogram Technologies
Zimmer Biomet Holdings, Inc. today announced that it is acquiring Monogram Technologies Inc., an orthopedic robotics company. The global medical technology developer will acquire all outstanding shares of Monogram for $4.04 a share, totaling an equity value of $177 million and an enterprise value of $168 million.
“Monogram’s technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation,” said Ivan Tornos, the chairman, president, and CEO of Zimmer Biomet. “Upon closing, our customer-centric portfolio will consist of the most comprehensive and flexible technology ecosystem to support the varying preferences of a vast array of surgeons — now and into the future.”
“With Monogram’s proprietary technology, Zimmer Biomet has the potential to become the first company to deliver fully autonomous capabilities and redefine both the standard of care and the future of orthopedic surgery,” he continued.
The respective boards of directors of Zimmer Biomet and Monogram unanimously approved the proposed transaction. Zimmer Biomet, which has offices in Montpelier, France, and Warsaw, Ind., offers its flagship ROSA platform. ROSA, which recently expanded into shoulder replacement, has four applications, including the knee.
Zimmer Biomet to incorporate Monogram tech into ROSA
Zimmer Biomet said it expects Monogram Technologies’ semi- and fully autonomous robotic technologies to add new and differentiated capabilities to expand its own surgical robot.
Monogram has developed a CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology. It earned FDA 510(k) clearance in March 2025. The Austin, Texas-based company said it expects to commercialize the mBôs technology with Zimmer Biomet implants in early 2027.
In addition, Monogram is developing a fully autonomous version of the mBôs system. It asserted that the technology could significantly increase safety, efficiency, and outcomes, as well as address applications beyond TKA.
“Since our inception, we have been singularly focused on advancing orthopedic robotics with technology designed to safely, efficiently, and accurately support surgeons with total knee arthroplasty,” said Benjamin Sexson, CEO of Monogram. “We are thrilled by the opportunity to add our technology to Zimmer Biomet’s leading portfolio of surgical robotics, navigation solutions, and trusted implants and to benefit from their deep industry expertise and global scale.”
Zimmer Biomet said it expects the acquisition to contribute to revenue growth in 2027 and beyond. The company noted that mBôs will aid robotic knee adoption in the U.S., increase its market share with a broader product range, and expand its global knee offerings.
Zimmer Biomet to expand ROSA applications
The proposed transaction expands Zimmer Biomet’s extensive suite of orthopedic robotics. This gives it access to systems and analytics to address the needs of surgeons pre-, intra-, and post-operatively. The company said its portfolio includes:
- Imageless robotics through its ROSA platform
- A licensed CT-based handheld robot
- Mixed reality navigation
- AI-based surgical navigation
- A pathway to advanced semi- and fully autonomous robotics capabilities.
Zimmer Biomet predicted that it will be able to address the diverse preferences of surgeons globally and multiple styles of surgical techniques. This includes CT and non-CT, robotic and non-robotic, and manual, surgeon-centered methods, or semi- or fully autonomous technologies.
The ROSA platform is rapidly approaching 2,000 installations worldwide, the company claimed. Zimmer Biomet said it is committed to continuing to advance the ROSA platform and is investing in a robust R&D pipeline featuring several new products and software applications expected between now and 2027.
This includes ROSA Knee with OptimiZe, which has been submitted to the FDA, and 510(k) clearance is anticipated later this year, as well as ROSA Posterior Hip and the full commercial launch of ROSA Shoulder. Zimmer Biomet has also worked with THINK Surgical Inc. on integrating the Persona system with the TMINI surgical robot.
